DrugBiological
Regramostim clinical trials
Also written rhGM-CSF.
- studies test it
- 12
- open now
- 0
- in phase 3
- 1
- first study started
- 2005
How studies write it
Studies that test it under each name
Development codes
Combined with it in one product
Studies by the year they started
12 studies that test it; most in 2009 (2)
| Year | Studies |
|---|---|
| 2005 | 1 |
| 2009 | 2 |
| 2010 | 1 |
| 2013 | 1 |
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 1 |
| 2021 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 1
- Phase 2
- 7
- Phase 3
- 1
- Phase 4
- 2
- No phase
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 5 · Other 7
Savara Inc. (2) · University of Wisconsin, Madison (2) · Peking University Cancer Hospital & Institute (1) · Xiamen Amoytop Biotech Co., Ltd. (1) · Changchun GeneScience Pharmaceutical Co., Ltd. (1) · Reponex Pharmaceuticals A/S (1) · Shandong Cancer Hospital and Institute (1) · The Affiliated Hospital of the Chinese Academy of Military Medical Sciences (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses regramostim is read from its arms, and is right about nine times in ten.
Testing it · 12
- Clinical Trial of Inhaled Molgramostim Nebulizer Solution in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)Active, not recruitingPhase 3Savara Inc.NCT04544293Written as Molgramostim Open-label
- Abscopal Effect of Radiation in Combination With rhGM-CSF for Metastatic Non-small Cell Lung CancerCompletedPhase 2Peking University Cancer Hospital & InstituteNCT03113851Written as rhGM-CSF
- Trial of Inhaled Molgramostim in Cystic Fibrosis Subjects With Nontuberculous Mycobacterial InfectionTerminatedPhase 2Savara Inc.NCT03597347Written as Molgramostim nebulizer solution
- Effect of rhGM-CSF on the Healing of Venous Leg UlcersStatus unknownPhase 2Reponex Pharmaceuticals A/SNCT04823962Written as rhGM-CSF + hydrogel
- Two-Arm Study of a DNA Vaccine Encoding Prostatic Acid Phosphatase (PAP) in Patients With Non-Metastatic Castrate-Resistant Prostate CancerCompletedPhase 2University of Wisconsin, MadisonNCT00849121Written as pTVG-HP with rhGM-CSF
- Prostatic Acid Phosphatase (PAP) Vaccine in Patients With Prostate CancerCompletedPhase 1University of Wisconsin, MadisonNCT00582140Written as pTVG-HP with rhGM-CSF
- A Study of SBRT in Combination With rhGM-CSF for Stage IV NSCLC Patients Who Failed in Second-line ChemotherapyWithdrawnPhase 2Wuhan UniversityNCT02623595Written as rhGM-CSF
- Chemotherapy Combination With Local Radiotherapy and rhGM-CSF for Oligometastatic Stage IV NSCLC PatientsStatus unknownNot applicableShandong Cancer Hospital and InstituteNCT03489616Written as rhGM-CSF
- RhGM-CSF as Adjuvant Immunotherapy in Treating Stage III Colon CancerStatus unknownPhase 2The Affiliated Hospital of the Chinese Academy of Military Medical SciencesNCT02466906Written as rhGM-CSF
- Antifugal Effect of Recombinant Human Granulocyte-macrophage Stimulating Factor (rhGM-CSF) in Patients Post Allo-HSCTCompletedPhase 4Xiamen Amoytop Biotech Co., Ltd.NCT01232504Written as rhGM-CSF group
- Recombinant Human Granulocyte Macrophage Colony Stimulating Factor(rhGM-CSF) Treating Oral MucositisStatus unknownPhase 2Wei LUONCT01806272Written as rhGM-CSF
- Efficacy and Safety Study of rhGM-CSF Gel to Treat Deep 2nd Thickness BurnCompletedPhase 4Changchun GeneScience Pharmaceutical Co., Ltd.NCT01785784Written as rhGM-CSF Gel
Given in every arm · 2 — regramostim is usual care beside what is tested
- A Personalized NeoAntigen Cancer Vaccine Combined With Anti-PD-1 in MelanomaStatus unknownPhase 1Xiangya Hospital of Central South UniversityNCT04072900Written as rhGM-CSF
- Study of Subcutaneous Injection of Low-dose rhGM-CSF +/- WLL in PAP.Status unknownPhase 2Shanghai Pulmonary Hospital, Shanghai, ChinaNCT01983657Written as rhGM-CSF
As the comparator · 1 — what is tested is compared with regramostim
Codes
What other systems call regramostim · ClinicalTrials.gg INT017088
- UNII (FDA) KR89Q40F01REGRAMOSTIMOne source FDA
- NCI Thesaurus C170366RegramostimOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | KR89Q40F01 | REGRAMOSTIM | One source FDA |
| NCI Thesaurus | C170366 | Regramostim | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.